Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
737 CHF | -0.14% | +5.06% | +8.22% |
Apr. 25 | EMS-Chemie Q1 Net Sales Decline | MT |
Feb. 14 | Bank Vontobel Lowers Price Target on EMS-Chemie, Maintains Hold Recommendation | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.8 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.22% | 18.8B | C+ | ||
+14.02% | 64.66B | A- | ||
-3.80% | 46.08B | A- | ||
+13.26% | 39.72B | B+ | ||
+19.28% | 25.82B | A- | ||
-1.13% | 17.14B | B+ | ||
-21.03% | 15.86B | A- | ||
+1.06% | 15.05B | B+ | ||
-16.73% | 14.14B | C+ | ||
-24.13% | 13.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMSN Stock
- Ratings EMS-CHEMIE HOLDING AG